Dr. Peter C. Trask, PhD, Speaking at CHIP Thursday, February 21, 2013

On Thursday, February 21, 2013, from 12:30 – 1:30 pm, the lecture series hosts Peter C. Trask, PhD, MPH, Director, Global Evidence & Value Development in Oncology, Sanofi, Inc., Cambridge, MA, who gives a lunchtime lecture about “In the Absence of Adherence: Identified Issues across the Cancer Continuum.”  This lecture is co-sponsored by UConn Department of Kinesiology and the Connecticut Children Medical Center.

The lecture will be in Video Conference Room 204 on the second floor of Ryan at 2006 Hillside Road at the University of Connecticut in Storrs.  For a map of the area, look at http://www.chip.uconn.edu/about/directions-to-chip/

You can also view this talk streamed live during or after the lecture at the following link:  https://mediasite.dl.uconn.edu/Mediasite/Play/32045d18dad2451b95f115d2e753e4fa1d

Peter TraskPeter Trask received his doctorate in Clinical Psychology from the University of Maine in 1997.  As a postdoctoral fellowship in Behavioral Medicine at the University of Michigan, he began a research program focused on assessing and treating emotional distress and changes in quality of life in individuals diagnosed with cancer; with his research studies focusing on a variety of cancer diagnoses and treatments. He continued this research, and provided therapy to cancer patients, during the subsequent four years that he was a faculty member in the Department of Psychiatry at the University of Michigan. In 2003, Dr. Trask moved from Michigan to Rhode Island to become an Assistant Professor of Research at Brown University in the Centers for Behavioral and Preventive Medicine. He continued to research issues of concern to cancer patients, while pursuing his Master’s in Public Health. Upon completion of his MPH from Brown University in 2005, Dr. Trask was employed in the Outcomes Research group in the Oncology Business Unit at Pfizer. During this time, he was responsible for developing strategies for assessing health economic and patient-reported outcomes for multiple early and late phase oncology compounds.  Most recently, he has continued this work as a Director in Oncology in the Global Evidence and Value Development group at Sanofi, Inc.